Sec Form 4 Filing - Kestenberg-Messina Kaitlin M. @ ADMA BIOLOGICS, INC. - 2024-03-31

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kestenberg-Messina Kaitlin M. 2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ ADMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) COO and SVP, Compliance (Last) (First) (Middle) C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, 3. Date of Earliest Transaction (MM/DD/YY) 03/31/2024 (Street) BOCA RATON, FL33487 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/31/2024 F 2,085 ( 1 ) D $ 6.6 112,190 ( 2 ) D Common Stock 04/01/2024 A 192,320 ( 3 ) A $ 0 304,510 ( 4 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 6.54 04/01/2024 A 300,328 ( 5 ) 04/01/2034 Common Stock 300,328 $ 0 300,328 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kestenberg-Messina Kaitlin M. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON, FL33487 COO and SVP, Compliance Signatures /s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as Attorney-in-fact 04/02/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. ( 2 )As of the transaction date, represents 112,190 shares of Common Stock acquired pursuant to the vesting of RSUs. ( 3 )These shares represent RSUs that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. ( 4 )Includes, as of the transaction date, (i) 192,320 RSUs granted on April 1, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (3); and (ii) 112,190 shares acquired pursuant to the vesting of RSUs. ( 5 )The option vests over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.